LORAZEPAM

Course overview

LORAZEPAM IS FDA-APPROVED FOR SHORT-TERM (4 MONTHS) RELIEF OF ANXIETY SYMPTOMS RELATED TO ANXIETY DISORDERS, ANXIETY-ASSOCIATED INSOMNIA, ANESTHESIA PREMEDICATION IN ADULTS TO RELIEVE ANXIETY OR TO PRODUCE SEDATION/AMNESIA, AND TREATMENT OF STATUS EPILEPTICUS. OFF-LABEL (NON-FDA-APPROVED) USES FOR LORAZEPAM INCLUDE RAPID TRANQUILIZATION OF THE AGITATED PATIENT, ALCOHOL WITHDRAWAL DELIRIUM, ALCOHOL WITHDRAWAL SYNDROME, INSOMNIA, PANIC DISORDER, DELIRIUM, CHEMOTHERAPY-ASSOCIATED ANTICIPATORY NAUSEA, AND VOMITING (ADJUNCT OR BREAKTHROUGH), AS WELL AS PSYCHOGENIC CATATONIA. THIS ACTIVITY COVERS LORAZEPAM, INCLUDING MECHANISM OF ACTION, PHARMACOLOGY, ADVERSE EVENT PROFILES, ELIGIBLE PATIENT POPULATIONS, AND MONITORING. IT ALSO HIGHLIGHTS THE INTERPROFESSIONAL TEAM'S ROLE IN MANAGING LORAZEPAM THERAPY.